Suppr超能文献

心脏遗传性疾病中β受体阻滞剂依从性的预测因素。

Predictors of β-blocker adherence in cardiac inherited disease.

机构信息

Department of Psychological Medicine, The University of Auckland, Auckland, New Zealand.

Green Lane Paediatric and Congenital Cardiac Services, Starship Children's Hospital, Auckland, New Zealand.

出版信息

Open Heart. 2018 Dec 16;5(2):e000877. doi: 10.1136/openhrt-2018-000877. eCollection 2018.

Abstract

OBJECTIVE

The cardiac inherited disease (CID) population has suboptimal adherence to long-term β-blocker therapy, which is known to be a risk for sudden cardiac death. This study aimed to identify the clinical and psychosocial variables associated with non-adherence in this population.

METHODS

130 individuals (aged 16-81 years, median: 54) from the New Zealand Cardiac Inherited Disease Registry taking β-blockers participated: 65 (50%) long QT syndrome, 42 (32%) hypertrophic cardiomyopathy and 23 (18%) other. Participants completed one questionnaire recording self-reported adherence, anxiety, depression, confidence in taking medication, illness perceptions and medication beliefs. Demographic and clinical variables were taken from the registry.

RESULTS

21 participants (16%) were classed as non-adherent. Bivariate analysis showed that self-reported adherence was worse in those who were younger (p<0.001), had a channelopathy not cardiomyopathy (p<0.01), reported lower confidence in taking β-blockers (p<0.001), had high concerns (p<0.05) and low necessity beliefs about their β-blocker (p<0.001), a poorer understanding of their CID (p<0.01), and lower treatment control beliefs (p<0.01). These variables accounted for 37% of the variance in adherence in a linear regression model. Stronger beliefs around medication necessity and higher confidence in their ability to take their medication predicted β-blocker adherence.

CONCLUSIONS

Factors associated with β-blocker non-adherence in patients with CID include young age, having a channelopathy, negative medication beliefs, low confidence in taking medication and poor illness perceptions. These findings present an opportunity to develop targeted interventions to improve adherence.

摘要

目的

患有遗传性心脏病(CID)的患者对长期β受体阻滞剂治疗的依从性较差,而这已知是导致心源性猝死的风险因素。本研究旨在确定与该人群药物依从性差相关的临床和心理社会因素。

方法

130 名来自新西兰遗传性心脏病登记处的正在服用β受体阻滞剂的患者参与了这项研究:65 名(50%)长 QT 综合征患者、42 名(32%)肥厚型心肌病患者和 23 名(18%)其他疾病患者。参与者完成了一份问卷,记录了他们的自我报告的依从性、焦虑、抑郁、对服药的信心、疾病认知和药物信念。人口统计学和临床变量取自登记处。

结果

21 名患者(16%)被归类为不依从。单变量分析显示,年龄较小的患者自我报告的依从性更差(p<0.001),患有通道病而不是心肌病(p<0.01),报告对服用β受体阻滞剂的信心较低(p<0.001),对β受体阻滞剂的关注度较高(p<0.05)和低必要性信念(p<0.001),对自身 CID 的理解较差(p<0.01),以及治疗控制信念较低(p<0.01)。在一个线性回归模型中,这些变量解释了依从性变化的 37%。对药物必要性的信念越强,对自己服药能力的信心越高,预测β受体阻滞剂的依从性越好。

结论

CID 患者β受体阻滞剂不依从的相关因素包括年龄较小、患有通道病、负面的药物信念、对服药的信心较低和较差的疾病认知。这些发现为开发旨在提高依从性的靶向干预措施提供了机会。

相似文献

1
Predictors of β-blocker adherence in cardiac inherited disease.心脏遗传性疾病中β受体阻滞剂依从性的预测因素。
Open Heart. 2018 Dec 16;5(2):e000877. doi: 10.1136/openhrt-2018-000877. eCollection 2018.
2
β-Blocker Adherence in Familial Long QT Syndrome.β受体阻滞剂在长 QT 综合征家族性中的应用
Circ Arrhythm Electrophysiol. 2016 Aug;9(8). doi: 10.1161/CIRCEP.115.003591.

引用本文的文献

1
Congenital Long QT Syndrome: A Focus on Risk Stratification and Management.先天性长QT综合征:聚焦于风险分层与管理。
Rev Cardiovasc Med. 2025 Jun 27;26(6):36779. doi: 10.31083/RCM36779. eCollection 2025 Jun.

本文引用的文献

1
β-Blocker Adherence in Familial Long QT Syndrome.β受体阻滞剂在长 QT 综合征家族性中的应用
Circ Arrhythm Electrophysiol. 2016 Aug;9(8). doi: 10.1161/CIRCEP.115.003591.
4
Social determinants of health in the setting of hypertrophic cardiomyopathy.肥厚型心肌病背景下的健康社会决定因素
Int J Cardiol. 2015 Apr 1;184:743-749. doi: 10.1016/j.ijcard.2015.03.070. Epub 2015 Mar 5.
6
Interventions for enhancing medication adherence.提高药物依从性的干预措施。
Cochrane Database Syst Rev. 2014 Nov 20;2014(11):CD000011. doi: 10.1002/14651858.CD000011.pub4.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验